Vertex Pharmaceuticals VRTX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 97th percentile, 5-year average -19.1x
#2195 of 2972 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 83rd percentile, 5-year average 6.5x
#4676 of 5311 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 84th percentile, 5-year average 9.8x
#4518 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 7.00 | – | 6.45 | 83% (pricier than usual) | #4676 of 5311 (1 = cheapest) |
| PE | 32.55 | 30.69 | -19.15 | 97% (pricier than usual) | #2195 of 2972 (1 = cheapest) |
| PS | 11.25 | 10.12 | 9.85 | 84% (pricier than usual) | #4518 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on VRTX.
Sign in to join the discussion.